<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011502</url>
  </required_header>
  <id_info>
    <org_study_id>MPBJI01</org_study_id>
    <nct_id>NCT03011502</nct_id>
  </id_info>
  <brief_title>InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS</brief_title>
  <acronym>OSIRIS</acronym>
  <official_title>InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaaT Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MaaT Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gut dysbiosis is an intestinal disorder that is characterized by accumulation of microbiota&#xD;
      imbalance, host-microbiota crosstalk dysfunction and inflammation.&#xD;
&#xD;
      As part of its clinical development, MaaT (Microbiota as a Therapy) Pharma is particularly&#xD;
      interested in patients with Bone and Joint Infections (BJI). These patients are treated with&#xD;
      antibiotics having significant consequences on their intestinal flora, causing intestinal&#xD;
      discomfort, which can be manifested by diarrhea.&#xD;
&#xD;
      MaaT Pharma wishes to carry out a clinical study, OSIRIS, in collaboration with Prof. Tristan&#xD;
      Ferry, member and coordinator of CRIOAc (Centre de Référence des Infections&#xD;
      Ostéo-Articulaires Complexes) Lyon, Center of Reference of Bone and Joint Infections (BJI).&#xD;
      The objective of this study is to follow patients with treated BJI in order to characterize&#xD;
      intestinal dysbiosis and the future relevance of an autologous Fecal Microbiota&#xD;
      Transplantation (aFMT) intervention.&#xD;
&#xD;
      To do this, patients will be monitored according to the current CRIOAc recommendations, with&#xD;
      the aim of taking biological samples from patients at the same time as scheduled visits,&#xD;
      routine monitoring patients. Only one additional consultation will be carried out 15 days&#xD;
      after stopping the antibiotics in order to better evaluate the dysbiosis evolution.&#xD;
&#xD;
      Thus biological samples (blood, stool, nasal, rectal) will be taken during the follow-up&#xD;
      consultations over a period of 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">March 27, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of intensity and frequency of Diarrheic Symptoms</measure>
    <time_frame>From baseline, up to 15 days after antibiotherapy treatment stop (Week 8 to week 14)</time_frame>
    <description>Assessment of the evolution of intensity and frequency of Diarrheic Symptoms from baseline, during antibiotic treatment (W2), at the end of treatment (W6-12) and 15 days after antibiotherapy treatment stop (W8-14)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of the gut dysbiosis and its prevalence in patients with BJI and under antibiotic treatment : measured by NGS (Next-Generation Sequencing) method</measure>
    <time_frame>Between baseline, after antibiotherapy treatment stop (Week 8-14) and the end of the follow-up (6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Bone and Joint Infection</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological samples collection of blood and feces</intervention_name>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consenting subjects with BJI (native or material related BJI) at participating sites&#xD;
             who are being treated with antibiotics as part of their standard treatment procedure&#xD;
             will be enrolled&#xD;
&#xD;
          -  The subject is willing, able to understand and comply to the protocol requirement&#xD;
&#xD;
          -  More than 18-years-old&#xD;
&#xD;
          -  Subject is suspected for implanted or native BJI and is eligible for antibiotics&#xD;
             treatment&#xD;
&#xD;
          -  Subject signed Inform Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe disease with a life expectancy &lt; 3 months&#xD;
&#xD;
          -  Antibiotherapy in the 14 days before inclusion in the study&#xD;
&#xD;
          -  Patient non-affiliated to health care system&#xD;
&#xD;
          -  Patient under the power of law&#xD;
&#xD;
          -  Guardianship, curators patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tristan Ferry, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH Diaconesses-Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>December 27, 2016</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

